doi:10.3969/j.issn.1673-8640.2018.07.021

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 7

[1]	LINCH D C.Burkitt lymphoma in adults[J].Br J Haematol,2012,156(6):693-703.
[2]	CAIRO M S, COIFFIER B, REITER A,et al.Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus[J].Br J Haematol,2010, 149(4) : 578-586.
[3]	DU J,WANG H,ZHONG C,et al.Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide[J]. Mol Immunol,2008, 45(10) : 2861-2868.
[4]	WILDES T M,FARRINGTON L,YEUNG C,et al.Rituximab is associated with improved survival in Burkitt lymphoma:a retrospective analysis from two US academic medical centers[J]. Ther Adv Hematol,2014,5(1):3-12.
[5]	RIZZIERI D A,JOHNSON J L, NIEDZWIECKI D, et al.Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of cancer and leukemia group B study 9251[J].Cancer,2004, 100(7): 1438-1448.
[6]	HAMILTON B,SERAFINO S, KALAYCIO M, et al.Early readmission rates after autologous and allogeneic hematopoietic progenitor cell transplantation(HPCT)[J]. Biology of Blood and Marrow Transplantation,2012, 18(2) : S279.
[7]	曾艳,马文菲,陈少华,等. 进行心包穿刺和引流的心包积液患者的临床特点分析[J]. 内科急危重症杂志,2011,17(5):276-278.

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 7

Related Articles 15

Recommended Articles

Metrics